BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 24770721)

  • 1. Dualistic classification of epithelial ovarian cancer: surgical and survival outcomes in a large retrospective series.
    Panici PB; Marchetti C; Salerno L; Musella A; Vertechy L; Palaia I; Perniola G; Ruscito I; Boni T; Angioli R; Muzii L
    Ann Surg Oncol; 2014 Sep; 21(9):3036-41. PubMed ID: 24770721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?
    Moss EL; Evans T; Pearmain P; Askew S; Singh K; Chan KK; Ganesan R; Hirschowitz L
    Int J Gynecol Cancer; 2015 Sep; 25(7):1201-7. PubMed ID: 26035124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period".
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Cuesta-Guardiola T; Peregrin I; Mendizabal E; Lizarraga S; Ortiz-Quintana L
    Surg Oncol; 2016 Mar; 25(1):49-59. PubMed ID: 26979641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
    Fotopoulou C; Zang R; Gultekin M; Cibula D; Ayhan A; Liu D; Richter R; Braicu I; Mahner S; Harter P; Trillsch F; Kumar S; Peiretti M; Dowdy SC; Maggioni A; Trope C; Sehouli J
    Ann Surg Oncol; 2013 Apr; 20(4):1348-54. PubMed ID: 23054114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
    Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary Cytoreduction in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Institution Experience.
    Musella A; Marchetti C; Palaia I; Perniola G; Giorgini M; Lecce F; Vertechy L; Iadarola R; De Felice F; Monti M; Muzii L; Angioli R; Panici PB
    Ann Surg Oncol; 2015 Dec; 22(13):4211-6. PubMed ID: 25801357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL17a and IL21 combined with surgical status predict the outcome of ovarian cancer patients.
    Chen YL; Chou CY; Chang MC; Lin HW; Huang CT; Hsieh SF; Chen CA; Cheng WF
    Endocr Relat Cancer; 2015 Oct; 22(5):703-11. PubMed ID: 26150382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laparoscopic versus open surgery for endometrial cancer: a minimum 3-year follow-up study.
    Ghezzi F; Cromi A; Uccella S; Siesto G; Giudici S; Serati M; Franchi M
    Ann Surg Oncol; 2010 Jan; 17(1):271-8. PubMed ID: 19826876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of Epithelial Ovarian Cancer: Time for Strategy Trials to Resolve the Problem of Optimal Timing of Surgery.
    Van de Putte G; Oben J; Prenen L; Schobbens JC; Vlasselaer J; Van Holsbeke C; Debrock G; Van Eycken P; de Jonge E
    Int J Gynecol Cancer; 2015 Jul; 25(6):993-9. PubMed ID: 25914962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer.
    Chung HH; Kwon HW; Kang KW; Park NH; Song YS; Chung JK; Kang SB; Kim JW
    Ann Surg Oncol; 2012 Jun; 19(6):1966-72. PubMed ID: 22124757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative morbidity and mortality in octogenarians with ovarian cancer.
    Walters CL; Schneider KE; Whitworth JM; Fauci JM; Smith HJ; Barnes MN; Straughn JM
    Int J Gynecol Cancer; 2013 Jul; 23(6):1006-9. PubMed ID: 23714708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does omentectomy in epithelial ovarian cancer affect survival? An analysis of the Surveillance, Epidemiology, and End Results database.
    McNally L; Teng NN; Kapp DS; Karam A
    Int J Gynecol Cancer; 2015 May; 25(4):607-15. PubMed ID: 25756404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
    Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
    Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.
    Chen X; Zhang J; Cheng W; Chang DY; Huang J; Wang X; Jia L; Rosen DG; Zhang W; Yang D; Gershenson DM; Sood AK; Bast RC; Liu J
    Int J Gynecol Cancer; 2013 Jun; 23(5):815-22. PubMed ID: 23669443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of neoadjuvant chemotherapy in the management of advanced ovarian cancer.
    Zhao D; Wu LY; Wang XB; Li XG
    Asian Pac J Cancer Prev; 2015; 16(6):2369-73. PubMed ID: 25824766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver resection for ovarian cancer liver metastases as part of cytoreductive surgery is safe and may bring survival benefit.
    Bacalbasa N; Dima S; Brasoveanu V; David L; Balescu I; Purnichescu-Purtan R; Popescu I
    World J Surg Oncol; 2015 Aug; 13():235. PubMed ID: 26243426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A detailed study of patients and tumor characteristics of epithelial ovarian cancer in Saudi women.
    Al-Badawi IA; Munkarah AR; Tulbah A; Babic II; Al Husaini H; Ahmad S
    Int J Gynecol Cancer; 2013 Mar; 23(3):456-60. PubMed ID: 23360812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
    Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
    Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage.
    Peres LC; Cushing-Haugen KL; Köbel M; Harris HR; Berchuck A; Rossing MA; Schildkraut JM; Doherty JA
    J Natl Cancer Inst; 2019 Jan; 111(1):60-68. PubMed ID: 29718305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesenteric lymph node involvement in advanced ovarian cancer patients undergoing rectosigmoid resection: prognostic role and clinical considerations.
    Gallotta V; Fanfani F; Fagotti A; Chiantera V; Legge F; Gueli Alletti S; Nero C; Margariti AP; Papa V; Alfieri S; Ciccarone F; Scambia G; Ferrandina G
    Ann Surg Oncol; 2014 Jul; 21(7):2369-75. PubMed ID: 24558070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.